🇺🇸 FDA
Patent

US 10093745

Anti-CSPG4 fusions with interferon for the treatment of malignancy

granted A61KA61K2039/505A61K38/212

Quick answer

US patent 10093745 (Anti-CSPG4 fusions with interferon for the treatment of malignancy) held by The Regents of the University of California expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K38/212, A61K38/215, A61K38/217